Alzheimer's Drug

George Russell Saturday April 9, 2022

Eisai's lecanemab, like Aduhelm, is a monoclonal antibody designed to remove beta-amyloid, a type of protein fragment that accumulates in brains

Jon Macaskill Tuesday June 8, 2021

Japan’s Eisai saw its US listed shares rise 56% – up by more than Biogen’s 38% jump after US regulators...

Notice

/var/www/asiafinancialcom/wp-content/themes/atf/archive.php

Asia Latest